Concepedia

Masayoshi Shirakawa

MS

7

Publications

122

Citations

7

H-Index

2013

Active since

Affiliations

MSD K.K. (Japan)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Teikyo University

Juntendo University

Boehringer Ingelheim (Japan)

Masayoshi Shirakawa is an author at MSD K.K. (Japan) specializing in cardiovascular disease, medicine, and pharmacology.

Top concepts

Publications per year

2013–2024

7

Publications

7

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia

Tamio Teramoto, Masayoshi Shirakawa, Masashi Kikuchi et al. · Atherosclerosis · 2013 · 29 citations

, , +8

The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study

Shigeru Kohno, Hiroyuki Bando, Fumihiko Yoneyama et al. · Journal of Infection and Chemotherapy · 2020 · 23 citations · Full text

Suvorexant for Reduction of Delirium in Older Adults After Hospitalization

Kotaro Hatta, Yasuhiro Kishi, Ken Wada et al. · JAMA Network Open · 2024 · 19 citations · Full text

Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia

Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki et al. · Atherosclerosis · 2017 · 16 citations · Full text

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia

Hidenori Arai, Tamio Teramoto, Hiroyuki Daida et al. · Atherosclerosis · 2016 · 12 citations

, , +10

Rows per page

1–5 of 7